Lynx1 Capital Management LP Cyma Bay Therapeutics, Inc. Transaction History

Lynx1 Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$10.86 - $17.62 $2.29 Million - $3.72 Million	-210,889 Reduced 17.5%	994,161 $14.8 Million
Q2 2023 Aug 14, 2023	SELL	$7.47 - $10.95 $1.23 Million - $1.81 Million	-164,877 Reduced 12.04%	1,205,050 $13.2 Million
Q1 2023 May 15, 2023	SELL	$5.88 - $9.59 $1.67 Million - $2.72 Million	-283,568 Reduced 17.15%	1,369,927 $11.9 Million
Q4 2022 Feb 14, 2023	SELL	$3.22 - $6.27 $2.16 Million - $4.22 Million	-672,338 Reduced 28.91%	1,653,495 $10.4 Million
Q3 2022 Nov 14, 2022	SELL	$2.77 - $4.25 $730,853 - $1.12 Million	-263,846 Reduced 10.19%	2,325,833 $8.14 Million
Q2 2022 Aug 15, 2022	BUY	$1.72 - $3.39 $2.07 Million - $4.07 Million	1,201,174 Added 86.51%	2,589,679 $7.64 Million
Q1 2022 May 16, 2022	BUY	$2.77 - $3.64 $452,997 - $595,274	163,537 Added 13.35%	1,388,505 $4.32 Million
Q4 2021 Feb 14, 2022	BUY	$3.23 - $4.6 $3.96 Million - $5.63 Million	1,224,968 New	1,224,968 $4.14 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Lynx1 Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Lynx1 Capital Management LP with notifications on news.